Table 4.
Frequency of comorbidities, chemotherapeutic drugs, and therapy cycles among adult cancer patients receiving chemotherapy in northwest Ethiopia oncology centers, 2022 (N = 406).
| Name of variables | Categories | Frequency (N) | Percent |
|---|---|---|---|
| BMI | Underweight | 115 | 28.3% |
| Normal weight | 251 | 61.8% | |
| Over weight | 40 | 9.9% | |
| Drug regimen | Alkylating agent with anthracycline | 96 | 23.6% |
| Taxane regimen alone | 113 | 27.8% | |
| Paclitaxel | 58 | 14.3% | |
| Docetaxel | 55 | 13.5% | |
| Taxane regimen with combination | 57 | 14% | |
| Platinum alone and with combination | 80 | 19.7% | |
| Vinca alkaloids | 42 | 10.3% | |
| Others | 18 | 4.4% | |
| Cycle of therapy | Second cycle | 117 | 28.8% |
| Third cycle | 98 | 24.1% | |
| Fourth cycle | 49 | 12.1% | |
| Fifth cycle | 71 | 17.5% | |
| Sixth and above | 71 | 17.5% | |
| Comorbidity | Yes | 61 | 15% |
| No | 345 | 85% |